Intelligent Relations
Preston by Intelligent Relations
Monica Stonehill
Gray shield icon
Is this you?
Claim your profile.

Monica Stonehill

Managing Editor

AS SEEN ON
Healio

Preston's Summary

Monica Stonehill is a Managing Editor at Healio. With a focus on medicine and healthcare, she covers a range of topics including oncology, immunotherapy, and digital health, while also delving into healthcare technology and alternative medicine. Stonehill's work has been featured in Healio, showcasing her expertise in various medical specialties.

Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston

Geo Focus

United States (National)

Coverage Attributes:

Beta
Informative: 33 %
Data Driven: 27 %
Events: 20 %
Interviews Q&as: 17 %

Themes Covered:

Not enough data icon

Not enough data

Most Recent Topics:

  • Hematology
  • Oncology
  • Immunotherapy
  • Digital Health
  • Telehealth

Pitching Insights

Monica Stonehill's coverage centers on healthcare and scientific topics, particularly in the fields of gastroenterology and hepatology. She frequently cites data to support her articles and relies on exclusive information.

Given Monica's focus, she would likely be interested in receiving pitches from experts who can provide insightful commentary or analysis about medical advances, liver diseases, digestive system issues, and developments within the fields of gastroenterology and hepatology. Sources with access to exclusive information or data-driven insights related to these areas may also capture her attention.

Monica appears not to have a specific geographic focus but instead focuses on global advancements in healthcare and scientific research within the specified fields.

This information evolves through artificial intelligence and human feedback. Improve this profile .

Articles

Healio

Combination treatment shows potential in KRAS wild-type serous ovarian cancer

Combination treatment shows potential in KRAS wild-type serous ovarian cancer

By: Monica Avila, Monica Stonehill

In this video, Monica Avila, MD, MPH, discusses results from the RAMP-201 trial of avutometinib and defactinib, which showed potential to expand its use to include patients with KRAS wild-type low-grade serous ovarian cancer.In May 2025, the FDA granted accelerated approval to avutometinib and defactinib (Avmapki Fakzynja Co-pack, Verastem Inc.) for KRAS-mutated recurrent low-grade serous ovarian

Healio

Letrozole alone fails to move forward as first-line option for ovarian cancer

Letrozole alone fails to move forward as first-line option for ovarian cancer

By: Monica Avila, Monica Stonehill

In this video, Monica Avila, MD, MPH, discusses results that showed letrozole alone was not noninferior to chemotherapy followed by letrozole for low-grade serous ovarian, fallopian tube or peritoneal carcinoma.In the phase 3, NRG-GY019 noninferiority trial, presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, patients with stage II to IV disease who underwent

© 2026 Intelligent Relations